Market Watch: Mesoblast shares down 14%
Monday, 31 October, 2011
The share price of stem cell specialists Mesoblast (ASX:MSB) shed 14% of its value in trading on Friday and today, down from $9.39 at Thursday’s close of trading to $8.25 as of midday today.
The drop was precipitated by Macquarie Research updating its rating for the biotech to “underperform”.
Other analysts have recently rated Mesoblast as “buy”, with Nomura setting a target price of $10.15 and Bell Potter $16.00 both only one month ago.
Late last year Mesoblast wowed the industry with its monumental deal with Cephalon, and recently announced it was partnering with Lonza to manufacture it’s off-the-shelf mesenchymal precursor stem cells.
Follow this link for a detailed profile of Mesoblast and its technology, and an interview with its CEO, Professor Silviu Itescu.
Does exercise really extend lifespan? It's complicated
Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...